Synergistic enhancement of osimertinib efficacy in non-small cell Lung cancer cells through Epigallocatechin-3-gallate: mechanistic insights into YAP/TEAD/CTGF axis inhibition
This study provides evidence that EGCG effectively targets the Hippo signaling pathway to overcome OSI resistance in NSCLC. The inclusion of EGCG in combinatorial therapies holds promise as a novel approach to combat therapeutic resistance and improve outcomes for patients with EGFR-mutated NSCLC.
Authors
- Ashwini Somayaji (ORCID: https://orcid.org/0000-0003-4541-0567)
- Chakrakodi Shashidhara Shastry (ORCID: https://orcid.org/0000-0002-2697-0449)
Institutions
- Nitte University (IN)
- M S Ramaiah University of Applied Sciences (IN)
Publication Details
- Journal
- Advanced Pharmaceutical Bulletin
- Published
- 2025-03-23
- DOI
- https://doi.org/10.34172/apb.43809
- Citations
- 1
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 1.15